Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1868 participants
INTERVENTIONAL
2008-02-06
2023-09-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The overall goal is to identify risk genes for dysglobulinemia, and more specifically Multiple Myeloma. This will involve the conservation of cells in a bank and genetic sequencing on samples obtained from families with at least two cases of dysglobulinemia. Material used for sequencing is likely to include fresh peripheral blood cells or lymphoblastoid lines established from peripheral blood lymphocytes of patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
NCT01109407
S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma
NCT00900263
Bleeding in Multiple Myeloma
NCT06482931
Multiple Myeloma Minimal Residual Disease
NCT02627261
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
NCT06212323
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Identification of genetic factors in dysglobulinemia cases
Genetic analysis of peripheral blood samples
M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genetic analysis of peripheral blood samples
M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 1 case alive at least
* biological material available for 1 case at least
* Patients give their informed consent
* attached to the French Health protection service
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles DUMONTET
Role: PRINCIPAL_INVESTIGATOR
Hospices Civils de Lyon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service d'Oncologie-Radiothérapie - CHU Pointe-à-Pitre/Abymes Guadeloupe
Pointe à Pitre, Guadeloupe, France
Service de Médecine Interne-Hématologie, CHU de Fort de France Fort de France
Fort-de-France, Martinique, France
CHU d'ABBEVILLE
Abbeville, , France
CHU Amiens Picardie
Amiens, , France
CHU Groupe Hospitalier Sud Hématologie Clinique
Amiens, , France
CH d'Avignon
Avignon, , France
CHU de Besançon
Besançon, , France
CH de Blois Service d'Hématologie
Blois, , France
Hôpital Avicenne Service d'Hématologie
Bobigny, , France
Service d'Hématologie clinique et Thérapie Cellulaire, CHU de BORDEAUX
Bordeaux, , France
CHU Morvan
Brest, , France
Service d'hématologie Clinique
Caen, , France
Hématolgie- Hôpital privé Cesson-Sévigné
Cesson-Sévigné, , France
CH William Morey, Service d'Hémato-Oncologie
Chalon-sur-Saône, , France
CHU de Chartres
Chartres, , France
Département d'Oncogénitique - Centre Jean Perrin
Clermont-Ferrand, , France
Hôpital Sud Francilien
Corbeil-Essonnes, , France
Service d'Hématologie Clinique, CHU de Dijon
Dijon, , France
Centre Hospitalier de Dunkerque
Dunkirk, , France
GHM, Institut Daniel Hollard
Grenoble, , France
CHU Albert Michallon
Grenoble, , France
Service d'Hématologie, CHU de Versailles
Le Chesnay, , France
Centre Jean Bernard Clinique Victor Hugo
Le Mans, , France
Service d'Onco-hématologie, Hôpital Saint-Vincent GH-ICL
Lille, , France
Service des Maladies du Sang CHU Lille
Lille, , France
Département d'Oncogénétique, Centre Paoli Calmettes
Marseille, , France
CHR-Metz-Thionville, Hôpital de Mercy, Service d'Hématologie
Metz, , France
CHU d'Annecy
Metz-Tessy, , France
Hôpital Saint-Eloi, Département d'Hématologie clinique
Montpellier, , France
Service d'Oncologie Médical, Centre Azuréen de Canrérologie-1
Mougins, , France
CHU-HÔTEL -Dieu de Nantes
Nantes, , France
Hôpital de l'Archet 1
Nice, , France
CHU Carémeau
Nîmes, , France
Institut Curie
Paris, , France
Hôpital St Antoine Service des maladies du Sang
Paris, , France
Jean Paul FermandService Immuno-Hématologie Hôpital Saint Louis
Paris, , France
Hospices Civils de Lyon
Pierre-Bénite, , France
CHU de Poitiers
Poitiers, , France
Hôpital Robert Debré Service du Professeur A. DELMER Hématologie Clinique
Reims, , France
CHU de Rennes Hôpital Sud
Rennes, , France
CH de Rodez
Rodez, , France
Hôpital de Saint- Germain en Laye
Saint-Germain-en-Laye, , France
Département d'Hématologie à l'Institut de Cancérologie de la Loire
Saint-Priest-en-Jarez, , France
Hôpital Purpan Service d'Hématologie
Toulouse, , France
Centre Hospitalier de Valence
Valence, , France
CHU de Nancy, Hôpital de Brabois
Vandœuvre-lès-Nancy, , France
Hôpital Privé de Villeneuve d'Ascq
Villeneuve-d'Ascq, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dumontet C, Demangel D, Galia P, Karlin L, Roche L, Fauvernier M, Golfier C, Laude MC, Leleu X, Rodon P, Roussel M, Azais I, Doyen C, Slama B, Manier S, Decaux O, Pertesi M, Beaumont M, Caillot D, Boyle EM, Cliquennois M, Cony-Makhoul P, Doncker AV, Dorvaux V, Petillon MO, Fontan J, Hivert B, Leduc I, Leyronnas C, Macro M, Maigre M, Mariette C, Mineur P, Rigaudeau S, Royer B, Vincent L, Mckay J, Perrial E, Garderet L. Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myelome study. Am J Hematol. 2023 Feb;98(2):264-271. doi: 10.1002/ajh.26785. Epub 2023 Jan 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-A00644-49
Identifier Type: OTHER
Identifier Source: secondary_id
2007-460
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.